

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Drug Program[®]

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|-----------------------------|-------------------------------|----------------------------|--|----------------|-------------|-------------------|
| Aczone® Gel 5%, 7.5% | NPD + PA + AL (Min Age 12) | NPD + PA | Three of the following generics: adapalene cream/gel, adapalene/benzoyl peroxide, clindamycin gel/lotion/solution, clindamycin/tretinoin, erythromycin/benzoyl peroxide, tretinoin cream/gel | No Change | AL Removal | 04/01/25 |
| Adbry® Inj 300/2ml | PB/SP* + PA | No Change (New Drug) | | No Change | No Change | 07/01/24 |
| allopurinol tab 200mg | NPD + PA | No Change (New Generic) | Generic allopurinol 100mg tablet | No Change | No Change | 09/16/24 |
| Austedo® XR Tab 18mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 07/15/24 |
| Austedo® XR Tab Titr Kit | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 07/15/24 |
| Clobetasol Sus 0.05% | NPD + PA | No Change (New Drug) | One generic ophthalmic steroid suspension (e.g., Prednisolone ophthalmic suspension, fluorometholone ophthalmic suspension, dexamethasone ophthalmic suspension) | No Change | No Change | 07/15/24 |

*= for Specialty plans

** = May be available as generic for certain plans

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

(continued)

(4/25 version)

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|---|-------------------------------|----------------------------|--|----------------|-------------|-------------------|
| Crexont® Cap | NPD + PA | No Change (New Drug) | Generic carbidopa/levodopa | No Change | No Change | 08/19/24 |
| dabigatran cap (Brand: Pradaxa®) | G | No Change (New Generic) | | No Change | No Change | 09/16/24 |
| Dapsone® Gel 5%, 7.5% | NPD + PA + AL (Min Age 12) | NPD + PA | Three of the following generics: adapalene cream/gel, adapalene/benzoyl peroxide, clindamycin gel/lotion/solution, clindamycin/tretinoin, erythromycin/benzoyl peroxide, tretinoin cream/gel | No Change | AL Removal | 04/01/25 |
| dasatinib tab (Brand: Sprycel®) | G/SP* + PA | No Change (New Generic) | | No Change | No Change | 09/09/24 |
| Ebglyss™ Inj 250/2ml Auto-Injector | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/23/24 |
| Ebglyss™ Inj 250/2ml Prefilled Syringe | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 11/11/24 |
| Entresto® Cap 6-6mg, 15-16mg | PB + QL (4 caps per day) | No Change (New Drug) | | No Change | No Change | 07/08/24 |
| Femlyv™ Tab 1/0.02mg | NPD | No Change (New Drug) | | No Change | No Change | 09/23/24 |
| glimepiride tab 3mg | G | No Change (New Drug) | | No Change | No Change | 09/09/24 |
| ivabradine tab 5mg, 7.5mg (Brand: Corlanor®) | G + PA | No Change (New Generic) | | No Change | No Change | 07/15/24 |
| Lazcluze® Tab 80mg, 240mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/02/24 |
| l-glutamine pow 5gm (Brand: Endari®) | G + PA | No Change (New Generic) | | No Change | No Change | 07/22/24 |

*= for Specialty plans

** = May be available as generic for certain plans

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

(*continued*) (4/25 version)

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|-----------------------------|----------------------------|-------------------|------------------------------|----------------|-------------|-------------------|
| Livdelzi® Cap | NPD/SP* + PA | No Change | | No Change | No Change | 08/19/24 |
| 10mg | | (New Drug) | | | | |
| Livmarli® Sol | NPD/SP* + PA | No Change | | No Change | No Change | 08/05/24 |
| 19mg/ml | | (New Drug) | | | | |
| lofexidine tab 0.18mg | G + QL + PA | No Change | Generic clonidine | No Change | No Change | 09/02/24 |
| (Brand: Lucemyra®) | (16 tabs per day) | (New Generic) | | | | |
| Miplyffa™ Cap | $NPD/SP^* + PA$ | No Change | | No Change | No Change | 09/30/24 |
| | | (New Drug) | | | | |
| Nemluvio [®] Inj | NPD/SP* + PA | No Change | | No Change | No Change | 08/19/24 |
| 30mg | | (New Drug) | | | | |
| Ohtuvayre™ Sus | NPD + PA + QL | No Change | | No Change | No Change | 07/08/24 |
| 3/2.5ml | (5ml per day) | (New Drug) | | | | |
| Omvoh® Solution | NPD/SP* + PA | PB/SP* + PA | | Brand Downtier | No Change | 01/20/25 |
| Auto-Injector 100mg/ml | | | | | _ | |
| Omvoh® Solution | NPD/SP* + PA | PB/SP* + PA | | Brand Downtier | No Change | 01/20/25 |
| Prefilled Syringe 100mg/ml | | | | | | |
| ondansetron tab | G | No Change | | No Change | No Change | 07/8/24 |
| 16mg ODT | | (New Drug) | | _ | | |
| Onyda™ XR Sus | NPD + PA + QL | No Change | ONE of the following: | No Change | No Change | 09/09/24 |
| 0.1mg/ml | (4ml per day) | (New Drug) | generic atomoxetine, | | _ | |
| _ | | | generic guanfacine ER, | | | |
| | | | generic clonidine ER | | | |
| Otezla® | PB/SP* + PA | No Change | | No Change | No Change | 08/05/24 |
| 20mg Tab | | (New Drug) | | | | |
| Otezla® Tab Starter Therapy | PB/SP* + PA | No Change | | No Change | No Change | 08/05/24 |
| Pack 4 X 10mg & 51 X 20mg | | (New Drug) | | | | |
| oxcarbazepin tab ER | G + PA | No Change | Generic oxcarbazepine tablet | No Change | No Change | 09/09/24 |
| (Brand: Oxtellar XR®) | | (New Generic) | | | | |

*= for Specialty plans ** = May be available as generic for certain plans

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

(continued)

(4/25 version)

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|--|----------------------------|----------------------------|---------------------------|----------------|-------------|-------------------|
| pot chloride tab | G | No Change | | No Change | No Change | 09/16/24 |
| 15meq ER | | (New Drug) | | | | |
| Retevmo® Tab | NPD/SP* + PA | No Change | | No Change | No Change | 08/12/24 |
| 40mg, 80mg, 120mg, 160mg | | (New Drug) | | | | |
| Scemblix® Tab 100mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 07/01/24 |
| Sofdra™ Gel 12.45% | NPD + PA | No Change (New Drug) | | No Change | No Change | 07/08/24 |
| Sotyktu [®] Tab 6mg | NPD/SP* + PA | PB/SP* + PA | | Brand Downtier | No Change | 01/20/25 |
| Taltz [®] Inj 20/0.25ml, 40/0.5ml | NPD/SP* + PA | PB/SP* + PA | | Brand Downtier | No Change | 01/20/25 |
| Taltz® Solution Auto-Injector 80mg/ml | NPD/SP* + PA | PB/SP* + PA | | Brand Downtier | No Change | 01/20/25 |
| Taltz [®] Solution Prefilled Syringe 80mg/ml | NPD/SP* + PA | PB/SP* + PA | | Brand Downtier | No Change | 01/20/25 |
| Tanlor [®] Tab 1000mg | Excluded | No Change (New Drug) | | No Change | No Change | 08/05/24 |
| tazarotene cre 0.05% (Brand: Tazorac® Cream) | G + AL (Max Age 25) | No Change (New Generic) | | No Change | No Change | 09/16/24 |
| Tremfya® Inj 200/2ml | PB/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/23/24 |
| Tryvio™ Tab 12.5mg | NPD + PA | No Change (New Drug) | | No Change | No Change | 09/09/24 |
| Tyenne [®] Inj 162mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 07/01/24 |
| Vafseo® Tab 150mg, 300mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 07/22/24 |

*= for Specialty plans

** = May be available as generic for certain plans

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

(continued)

(4/25 version)

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|---------------------------------|-----------------------------------|-------------------------|---|----------------|-------------|-------------------|
| Veltassa® Pow 1gm | NPD | No Change (New Drug) | | No Change | No Change | 09/16/24 |
| Vigafyde™ Sol 100mg/ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 08/12/24 |
| Voranigo® Tab 10mg, 40mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 08/19/24 |
| Yorvipath® Inj | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/09/24 |
| Zepbound® Inj 2.5mg, 5/0.5ml | NPD + PA + QL (0.08ml per day) | No Change (New Drug) | | No Change | No Change | 08/12/24 |
| Zoryve® Cream 0.15% | NPD + PA | No Change (New Drug) | ALL of the following: generic topical steroid (e.g., triamcinolone, clobetasol, halobetasol, etc.), generic tacrolimus ointment/ Pimecrolimus cream, Eucrisa® (crisaborole) ointment. | No Change | No Change | 07/15/24 |

*= for Specialty plans ** = May be available as generic for certain plans

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

Abbreviation Key

| 0 | Conoria |
|---|--|
| G | Generic |
| LCG | Low Cost Generic. Benefit may vary; not all plans provide this incentive. |
| ACA | Affordable Care Act preventative drugs |
| РВ | Preferred Brand |
| NPD | Non-Preferred Drug |
| SP | Specialty Drug. Specialty Tier cost-share will apply for those benefits that have a prescription drug specialty tier. |
| PA | Prior Authorization is required. |
| MME | Morphine Milligram Equivalent |
| D/S | Days Supply Limit |
| QL | Quantity Limit |
| AL | Age Limit |
| Generic Addition | A generic drug that recently became available in the marketplace |
| Generic Downtier | This generic drug will be covered at the appropriate preferred drug level of cost-sharing. |
| Generic Uptier | This generic drug will be covered at the appropriate non-preferred drug level of cost-sharing. |
| Authorized Generic Addition | An authorized generic drug that recently became available in the marketplace |
| Authorized Generic Uptier | Authorized generics are brand drugs that are marketed without the brand name on its label. An authorized generic may be marketed by the brand name drug company, or another company with the brand company's permission. Unlike a standard generic drug, the authorized generic is not approved by the Food and Drug Administration (FDA) abbreviated new drug application process (ANDA). This authorized generic drug will be covered at a higher level of cost-sharing similar to other brand name drugs. |
| Brand Downtier | These brand drugs were added to the formulary as of the date indicated and are covered at the appropriate preferred brand formulary level of cost-sharing. |
| Brand Uptier | These brand drugs will be covered at the appropriate non-preferred drug level of cost-sharing. |
| Brand Addition | Coverage was added to this drug. |
| Brand/Authorized Generic/ Generic Deletion | Coverage was removed from this drug. Formulary alternatives are available. |